AMDA energía Selects Ideematec to Supply Solar Tracking Systems for 100MW Agri-PV Project Portfolio
Ideematec Inc., the leading global supplier of solar tracking systems, today announced it was selected by project developer AMDA energía (AMDA) to provide customized solar tracking systems for a 100 megawatt (MW) agro photovoltaics (Agri-PV) project portfolio located in France. The innovative systems will deliver synergistic solutions for the production of organic food crops and clean electricity generation all while providing soil protection and water savings, helping farmers to move towards a low-emissions smart farming labelling.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005876/en/
(Photo: Business Wire)
The 100 MW portfolio will be composed of multiple 5 MW projects and will meet specific requirements for proper construction on agricultural land in accordance with local regulations.
Ideematec’s engineering team has modified and optimized the Horizon L:TEC tracker model by adjusting the axis heights of the tracker and maximizing the rotation angle for the module to +/- 70 degrees, allowing the trackers to operate synergistically with agricultural equipment. Ideematec also designed an Agri-PV-specific control and agronomic-orientated monitoring system to improve crop production, land quality and address specific needs of each Agri-PV project site.
“Agri-PV projects require flexibility in both the hardware and installation to protect the integrity of the land and ensure that agricultural practices can operate effectively, while harnessing the benefits of clean energy,” said Jorge Gutiérrez Serra, President for AMDA. “We are confident that Ideematec’s durable and customizable solar trackers will fit the needs of an innovative energy system optimized for highly profitable agricultural production for years to come.”
“Our two-in-portrait (2P) module wings, equipped with bifacial modules, allow us to space module rows to support efficient agricultural operations, such as moving large vehicles between module rows, or monitoring sites for agricultural variables to increase generation efficiency,” says Mario Eckl, Co Founder & CEO Ideematec. “These innovations allow our trackers to provide reliable clean energy to projects at scale, without disturbing the local environment or quality of land. The Agri-PV sector is poised for tremendous growth and we are eager to support agricultural-friendly solutions.”
Agricultural-friendly utility-scale solar solutions are growing in popularity in Europe, and Ideematec expects that trend to erupt in both the North American and APAC markets in the coming years, as rural communities find ways to support scaled renewable energy deployment and generate multiple sources of revenue with agricultural lands.
About Ideematec, Inc.
Ideematec, Inc. is a trusted global supplier of solar tracking systems, headquartered in Germany. Established in 2003, the company serves as a pure play tracker provider for the utility-scale sector. Ideematec pioneered the 2P high-span safeTrack Horizon™ tracker, powered by a patented dual drive technology. Since 2017, the company has successfully delivered some of the biggest solar facilities on three continents, including Jordan (250 MW), Australia (350 MW) and Spain (200 MW). For more information please visit: http://www.ideematec.com/
About AMDA energía
AMDA energía is an international global developer focused on the promotion, development and funding of renewable energy generation projects around the world with proven track record in both photovoltaic and wind sectors having developed more than 30 projects in on 3 different continents since it was created in 2008 (Spain, Portugal, France, South Africa, Mozambique, Tunisia, Colombia, Mexico). Thanks to its experienced staff, the core activities cover the complete process of development of a large-scale renewable energy project.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005876/en/
Contact information
Evelyn Kroiss
PR@ideematec.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release
Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 08:00:00 EET | Press release
Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It proves a supplier has undergone an exhaustive audit of its governance, security controls, and operational processes. For Dutch financial institutions, this qualificatio
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 04:00:00 EET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 03:00:00 EET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom